However, in patients with hepatocellular carcinoma (HCC), how MTT promotes the patients' antitumor immunity remains unknown.<h4>Methods</h4>In this study, we enrolled four patients to receive MTT and three patients to receive radiofrequency ablation (RFA), aiming to explore the mechanism by which MTT promotes antitumor immunity.<h4>Results</h4>We found that MTT significantly prolonged the patients' PFS compared with RFA and identified a novel T cell subset characterized by CX3CR1 and GPR56 that specifically correlated with the efficacy of MTT. This evidence concerns the gene CX3CR1 and hepatocellular carcinoma.